"Factor Xa Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Endogenous factors and drugs that inhibit or block the activity of FACTOR XA.
| Descriptor ID |
D065427
|
| MeSH Number(s) |
D27.505.519.389.745.800.449.500 D27.505.954.502.119.500.500
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Factor Xa Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Factor Xa Inhibitors".
This graph shows the total number of publications written about "Factor Xa Inhibitors" by people in this website by year, and whether "Factor Xa Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 0 | 1 |
| 2002 | 1 | 0 | 1 |
| 2004 | 2 | 0 | 2 |
| 2008 | 1 | 0 | 1 |
| 2009 | 0 | 3 | 3 |
| 2010 | 1 | 0 | 1 |
| 2011 | 1 | 1 | 2 |
| 2013 | 0 | 1 | 1 |
| 2014 | 1 | 0 | 1 |
| 2015 | 1 | 3 | 4 |
| 2016 | 3 | 2 | 5 |
| 2017 | 2 | 2 | 4 |
| 2018 | 1 | 2 | 3 |
| 2019 | 2 | 3 | 5 |
| 2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Factor Xa Inhibitors" by people in Profiles.
-
The AAST prospective observational multicenter study of the initial experience with reversal of direct oral anticoagulants in trauma patients. Am J Surg. 2021 08; 222(2):264-269.
-
Delayed Intracranial Hemorrhage in Anticoagulated Geriatric Patients After Ground Level Falls. J Emerg Med. 2019 Dec; 57(6):812-816.
-
Safety, efficacy, and cost of four-factor prothrombin complex concentrate (4F-PCC) in patients with factor Xa inhibitor-related bleeding: a retrospective study. J Thromb Thrombolysis. 2019 Aug; 48(2):250-255.
-
Clinical consequences of bleeding among individuals with a recent acute coronary syndrome: Insights from the APPRAISE-2 trial. Am Heart J. 2019 09; 215:106-113.
-
AGA Clinical Practice Update: Coagulation in Cirrhosis. Gastroenterology. 2019 07; 157(1):34-43.e1.
-
Extended-duration betrixaban versus shorter-duration enoxaparin for venous thromboembolism prophylaxis in critically ill medical patients: an APEX trial substudy. Intensive Care Med. 2019 04; 45(4):477-487.
-
Effectiveness and safety of rivaroxaban vs. warfarin in patients 80+ years of age with non-valvular atrial fibrillation. Eur Heart J Qual Care Clin Outcomes. 2018 10 01; 4(4):328-329.
-
Association of Anemia with Venous Thromboembolism in Acutely Ill Hospitalized Patients: An APEX Trial Substudy. Am J Med. 2018 08; 131(8):972.e1-972.e7.
-
Extended-Duration Betrixaban Reduces the Risk of Rehospitalization Associated With Venous Thromboembolism Among Acutely Ill Hospitalized Medical Patients: Findings From the APEX Trial (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban Trial). Circulation. 2018 01 02; 137(1):91-94.
-
Thrombus Burden of Deep Vein Thrombosis and Its Association with Thromboprophylaxis and D-Dimer Measurement: Insights from the APEX Trial. Thromb Haemost. 2017 12; 117(12):2389-2395.